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Abstract: Lung cancer classification during the last four decades 
has undergone major changes and evolution, mostly lead by patholo-
gists who were actively involved in the International Association 
for the Study of Lung Cancer (IASLC) Pathology Committee. The 
Committee members have led the development and writing of the sec-
ond (1981), third (1999 and 2004), and fourth (2015) editions of the 
World Health Organization classifications on lung tumors. Committee 
members were responsible for defining and refining the classifications 
of small-cell carcinoma and adenocarcinoma subtypes that are rel-
evant to their clinical behavior. Particularly notable was development 
of the 2011 IASLC/American Thoracic Society/European Respiratory 
Society international, multidisciplinary lung adenocarcinoma classi-
fication. The multidisciplinary approach that represents the IASLC 
culture in research, education, and practice in clinical management 
of lung cancer patients have paved the way for integrating pathology 
practice into the new era of personalized cancer care.
Key Words: World Health Organization classification, 
Histopathology, Molecular pathology, Epidermal growth factor 
receptor, Anaplastic lymphoma kinase.
(J Thorac Oncol. 2014;9: 1740–1749)
The International Association for the Study of Lung Cancer (IASLC) was established in 1974 to promote all aspects of 
research in lung cancer and thoracic malignancies and improve 
lung cancer patient outcome through prevention, better diag-
nosis, and treatment. As an international and multidisciplinary 
organization, the pathology community was engaged to play 
a role in this effort. The development and role of Pathology 
Committee has been an evolution, with large parts being inti-
mately associated with the development of lung cancer clas-
sification during the last four decades (Fig. 1). However, with 
more recent advances on molecular diagnoses in lung cancer, 
the committee has also assumed leadership roles in the devel-
opment of guidelines and standards on molecular testing for 
lung cancer. This article is meant to highlight and archive 
some of the important works and roles that IASLC Pathology 
Committee and its members have undertaken, in the context 
of the 40th Anniversary of IASLC.
EVOLUTION OF IASLC PATHOLOGY  
PANEL/COMMITTEE
1970s and 1980s
In 1982, the Pathology Panel of the IASLC was offi-
cially recognized by the IASLC Board and approved by the 
General Assembly as recorded in the IASLC Newsletter, 
September 29, 1982. However, leading up to this event, a group 
of lung cancer pathology experts (Fig. 2) coordinated by Dr. 
Raymond Yesner (New Haven, CT) had already been working 
together on the lung cancer classification. In 1977, Dr. Yesner 
was asked by the World Health Organization (WHO) to be 
the chairman of the 2nd edition of the WHO classification of 
lung tumors and to coordinate this group through 1981, when 
the World Health Organization, Histological Typing of Lung 
Tumours, 2nd edition was published.1
After the 1981 WHO classification was published, a 
proposal was made to the IASLC Board to form a Pathology 
Panel by Drs. Mary J. Matthews, Fred R. Hirsch, Adi Gazdar, 
Yukio Shimosato, and Raymond Yesner. The purpose of the 
Panel at that time was summarized in Table 1. After formal 
constitution of the Panel, the group focused on the classifica-
tion of small-cell lung cancer (SCLC) and its subtypes: the 
classical “oat cell” carcinoma (lymphocyte-like), the inter-
mediate subtype, and the combination of SCLC and non–
small-cell lung cancer (NSCLC).2 Based on ongoing cell line 
studies, mainly performed at the National Cancer Institute, 
Bethesda, MD, evidence emerged that there were significant 
biologic differences between classical oat cell carcinoma 
(“classical” cell lines) and the intermediate subtypes (corre-
sponding to “variant” cell lines).3 The biologic differences in 
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characteristics of the cell lines encouraged the IASLC pathol-
ogy group to evaluate differences in clinical characteristics 
for SCLC patients having classical oat cell carcinoma versus 
those with intermediate subtypes. The latter morphologic sub-
type was also termed 22/40 based on the mixture of SCLC (in 
the WHO classification termed 22) and the large-cell carci-
noma (in the WHO classification termed 40). Some clinical 
studies were performed showing that patients with tumor of 
the 22/40 subtype had a poorer response to chemotherapy and 
shorter survival compared with patients with the pure SCLC 
morphology.2,4 However, other studies showed no difference, 
and the IASLC Pathology Panel tried to determine whether 
the differences in clinical outcome were based on different 
histopathologic interpretation of the WHO subtypes.5 Several 
publications were made from the IASLC pathology group on 
this issue including a proposal for modification of the histo-
logic subclassification of small-cell carcinoma.2,6 However, 
through these studies, the morphologic and biologic hetero-
geneity of malignant lung tumors was recognized, and further 
studies emerged demonstrating the heterogeneity in NSCLC.7 
Clinical studies emerged and also demonstrated chemotherapy 
effect of certain histologic subtypes of NSCLC, and the tasks 
for the IASLC Pathology Panel expanded as more patholo-
gists became involved in its activity (Table 2).
FIGURE 1.  IASLC contribution to the progress made in pathology of thoracic malignancies during the last 40 years. Upper 
panel illustrates the milestone in histologic classification of lung cancer and contribution by members of IASLC pathology 
committee. Lower panel highlights major progress in pathology research during each decade since 1970s. IASLC, International 
Association for the Study of Lung Cancer; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
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1990s–2005
The late Dr. Mary Matthews served as the first Panel 
chairman until the 1991 sixth World Conference on Lung 
Cancer (WCLC) in Melbourne, Australia, when Dr. Fred 
Hirsch assumed chairmanship for the period of 1991–1998. In 
1994, with the encouragement of Dr. Shimosato, two projects 
were initiated that focused on lung neuroendocrine tumors 
and adenocarcinoma. This led to a series of publications on 
lung neuroendocrine tumors from the Panel as well as new 
ideas that contributed to revisions in the 1999 WHO classi-
fication. During this period, new members were recruited to 
the committee including those shown in Table 2. In 1996, Dr. 
Travis was asked by the WHO to coordinate the revision of the 
international classification of lung tumors, and a collaboration 
between WHO and IASLC was initiated.8
Between 1994 and 1998, the Panel members contrib-
uted and reviewed a group of neuroendocrine lung tumors and 
adenocarcinomas (Fig. 3) allowing for development of better 
FIGURE 2.  World Health Organization Expert Committee on Lung Cancer, Geneva, Switzerland, October 24, 1977: standing 
(right to left): Raymond Yesner, Chairman (USA); Dr. Wong (WHO); Roger Seal (Wales); WHO Representative; Herbert Spencer, 
MD (England); Leslie Sobin (WHO), Leiv Kreyberg (Norway); Yukio Shimosato (Japan); P. Mirejovsky (Czechoslovakia); E. Chaves 
(Brazil); J. Chretien (France); and K. Shanmugaratnam (Singapore). Seated (right to left): Dr. Sobin’s secretary; L. G. Olchovskaya 
(USSR); Mary Matthews (USA); L. Hochholzer (USA); and O. Campobasso (Italy). WHO, World Health Organization.
TABLE 1.  Purpose of IASLC Pathology Panel
Purpose of panel 1983a
  1. To encourage research activities concerning surgical and experimental pathology of lung cancer
  2. During slide circulation and workshops define a more exact histopathologic interpretation and classification of lung tumors within the IASLC
  3. To offer individuals and study groups a panel evaluation of histologic/cytologic material from lung cancer to make a uniform basis for comparing clinical 
and paraclinical studies from the several investigations within IASLC.
  4. Postgraduate training education in lung cancer pathology.
Purpose of panel 2005b
  1. To provide international leadership in the clinical and scientific aspects of lung cancer pathology
  2. To support the organization of the IASLC: its projects, publications, and meetings
  3. To be integrated with other specialties: surgery, oncology, radiation therapy, and molecular biology
  4. To play a central role in major publications (especially WHO classification efforts) in the field of lung cancer and other thoracic tumors
aIASLC Newsletter, November 1983.
bPresentation to the IASLC Board, March 2005 by Dr. Travis.
IASLC, International Association for the Study of Lung Cancer; WHO, World Health organization.
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TABLE 2.  IASLC Pathology Panel/Committee Membership and Accomplishments
Year Chairperson Members Major Accomplishment
Publications  
(See Reference List)
1983–1991 Mary Matthews 
(USA)a
Members of 1981 
WHO Lung Tumor 
Expert Committee 
on Lung Cancera
Seena Aisner (USA), Onofrio Campopbasso (Italy),a 
Bryan Corrin (UK), J. D. Elema (Netherlands), Adi 
Gazdar (USA), Samuel P. Hammar (USA), Fred R. 
Hirsch (Denmark), Bruce Mackay (USA), Magnus 
Nasiell (Sweden), Mary Sheppard (UK), Yukio 
Shimosato (Japan), Richard H. Steele (Australia), 
Raymond Yesner (USA),a and L. Zettergren 
(Sweden)
Second edition of WHO 
Classification of Lung Tumors 
(published in 1981)
1991–1998 Fred R. Hirsch 
(Denmark)
Seena Aisner (USA), Emilio Alvarez-Fernandez 
(Spain), Elisabeth Brambilla (France), Thomas 
V. Colby, M.D. (USA), Bryan Corrin (UK), Adi 
Gazdar (USA), Samuel P. Hammar (USA), Philip 
S. Hasleton (UK), Bruce Mackay (USA), Helmut 
Popper (Austria), Mary Sheppard (UK), Yukio 
Shimosato (Japan), Richard Steele (Australia), and 
William D. Travis (USA)
Third edition of WHO 
Histological typing of lung and 
pleural tumours (published in 
1999)
6,10,15,42
1999–2005 William D. Travis 
(USA)
Seena Aisner (USA), Emilio Alvarez-Fernandez, 
Madrid (Spain), Elisabeth Brambilla (France), 
Thomas V. Colby, MD (USA), Bryan Corrin (UK), 
Wilbur Franklin (USA), Adi Gazdar (USA), Fred 
Hirsch (USA), Samuel P. Hammar (USA), Philip S. 
Hasleton (UK), Masayuki Noguchi (Japan), Helmut 
Popper (Austria), and Mary Sheppard (UK)
WHO Classification of Tumors—
Pathology and Genetics, 
Tumours of the Lung, Pleura, 
Thymus and Heart (published 
in 2004)
IASLC/ASCO Workshop on 
bronchiolo-alveolar carcinoma 
(New York, November 2004)
23,43
2005–2009 Elisabeth Brambilla 
(France)
Douglas B. Flieder (USA), Wilbur Franklin (USA), 
Adi Gazdar (USA), Kim R. Geisinger (USA), Philip 
S. Hasleton (UK), Douglas Henderson (Australia), 
Bruce E. Johnson (USA), Andrew Nicholson (UK), 
Masayuki Noguchi (Japan), Victor Roggli (USA), 
F. B. J. M. Thunnissen (Netherlands), William D. 
Travis (USA), and Ming-Sound Tsao (Canada)
IASLC International Workshop 
on Advances in Pulmonary 
Neuroendocrine Tumors, 
Brompton Hospital, United 
Kingdom (Proceeding 
published in 2007).
IASLC/ATS/ERS International 
multidisciplinary classification 
of lung adenocarcinoma. 
(published in 2011)
24,25,44–49
2009–2011 Masayuki Noguchi 
(Japan)
Seena Aisner (USA), Elisabeth Brambilla (France), 
Federico Cappuzzo (Italy), Lucian Chirieac (USA), 
Fred Hirsch (USA), Kim Geisinger (USA), Keith 
Kerr (UK), Iver Petersen (Germany), Andrew 
Nicholson (UK), Masayuki Noguchi (Japan), Victor 
Roggli (USA), Erik Thunnissen (Netherland), 
William D. Travis (USA), Ming-Sound Tsao 
(Canada), Ignacio Wistuba (USA), and Yasushi 
Yatabe (Japan)
2011–2013 Ming-Sound Tsao 
(Canada)
Seena Aisner (USA), Elisabeth Brambilla (France), 
Lucian Chirieac (USA), Sanja Dacic (USA), Rafal 
Dziadziuszko (Poland), Kim Geisinger (USA), 
Fred Hirsch (USA) Keith Kerr (UK), Yuichi 
Ishikawa (Japan), Iver Petersen (Germany), Andrew 
Nicholson (UK), Masayuki Noguchi (Japan), Victor 
Roggli (USA), Erik Thunnissen (Netherland), Kafai 
To (China/Hong Kong), William D. Travis (USA), 
Ignacio Wistuba (USA), and Yasushi Yatabe (Japan)
CAP/IASLC/AMP guideline on 
EGFR and ALK testing for 
lung cancer patients (published 
in 2013)
IASLC ATLAS of ALK Testing 
in lung cancer. (published in 
2014)
26–28
2013–2015 Andrew Nicholson 
(UK)
Mary Beth Beasley (USA), Elisabeth Brambilla 
(France), Johan Bottling (Sweden), Lucian  
Chirieac (USA), Sanja Dacic (USA), Kim Geisinger 
(USA), Fred Hirsch (USA), Giuseppe Pelosi 
(Italy), Keith Kerr (UK), Yuichi Ishikawa (Japan), 
Nirush Lertprasertsook (Thailand), Andre Moreira 
(USA), Masayuki Noguchi (Japan), Iver Petersen 
(Germany), Erik Thunnissen (Netherland), Kafai 
To (China/Hong Kong), William D. Travis (USA), 
Ignacio Wistuba (USA), and Yasushi Yatabe (Japan)
WHO Classification: Pathology 
and Genetics: Tumours of 
the Lung, Pleura, Thymus 
and Heart. 4th edition (to be 
published in 2015)
50
aIASLC Newsletter, November 1983.
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understanding of these tumors and consensus on the histologic 
subclassification. These efforts and the publication document-
ing 100% 5-year survival for solitary small peripheral bron-
chioloalveolar carcinomas (BACs)9 led to major revisions in 
criteria for neuroendocrine lung tumors and adenocarcinoma 
adopted in the 1999 WHO classification. Collaborations 
among panel members resulted in a number of publications 
that contributed to our better understanding of the clinical, 
biologic, and molecular aspects of lung cancer.10–20 The panel 
for the 1999 WHO Histologic Typing of Tumours of the Lung 
and Pleura consisted of the IASLC panel as well as additional 
members added for broader expertise and international repre-
sentation (Table 2). Dr. Travis became chair of the Pathology 
Panel in 1999 and the panel met once or twice a year to address 
problems in the pathology of lung tumors.
In 2003, Drs. Travis and Brambilla were asked to be 
co-editors of the 2004 WHO Blue Book on classification 
of tumors, together with Drs. H. Konrad Műller-Hermelink 
(Wűrzburg, Germany) and Curtis C. Harris (Bethesda, MD). 
For this effort in addition to members of the IASLC Pathology 
Panel, almost 200 co-authors were involved in the writing 
of this document.21 A writing committee of the lead authors 
and staff from the International Association for Research on 
Cancer met in March of 2004 in Lyon, France to assemble the 
book (Fig. 4).
In November 4, 2004, at a multidisciplinary workshop 
on BAC22 sponsored by the IASLC and the American Society 
of Clinical Oncology, the IASLC Pathology Panel co-chaired 
by Drs. Travis and Franklin worked closely with a panel of 
radiologists coordinated by Dr. Kavita Garg (Denver, CO) 
to address problems in classification of BAC and lung ade-
nocarcinoma.23 In preparation for this meeting, a panel of 
pathologists met at the Armed Forces Institute of Pathology in 
August of 2004 to review histologic slides from a set of lung 
adenocarcinomas contributed for the workshop (Fig. 5). The 
pathology group reviewed a series of 131 cases with surgi-
cal biopsies and computed tomography scans and a consen-
sus document was published in 2005.23 In 2005, the IASLC 
Pathology Panel was reformed (Table 2, 2005–2009) and Dr. 
Brambilla became the Chair and Dr. Noguchi the Chair-Elect.
2005 to Present
As a follow-up of the Bronchioloalveolar Workshop 
meeting, the panel organized a series of meetings and work-
shop to address the classification of pulmonary neuroendo-
crine tumors and adenocarcinoma. An IASLC International 
Symposium on Advances in Pulmonary Neuroendocrine 
Tumors was held in December 2007 at the Royal Brompton 
Hospital in London, United Kingdom.24 The meeting, led by 14 
international faculties in the disciplines of pathology, surgery, 
medicine, oncology, endocrinology, nuclear medicine, diag-
nostic imaging, and biostatistics aimed to develop the IASLC 
International Pulmonary Neuroendocrine Tumors Registry. 
The meeting highlighted the difference in presentation of the 
tumors, management options for early and advanced stage 
disease including the use of novel agents and approaches. 
FIGURE 3.  World Health Organization Panel for 1999 WHO Classification: left to right: Helmut Popper, Emilio Alvarez 
Fernandez, Yukio Shimosato, Bryan Corrin, Bruce Mackay, Fred Hirsch, Elisabeth Brambilla, Thomas Colby, William Travis, 
Samuel Hammar, Philip Hasleton, and Richard Steele.
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The need, process, and approach to an International Registry 
were emphasized. International collaboration to develop a ret-
rospective registry, prospective data collection, virtual tissue 
bank, and collaborative clinical trials were universally agreed 
as the best way to advance our understanding and treatment of 
these rare tumors. These recommendation remains as an ongo-
ing project for the current Pathology Committee.
The concept of developing the next version of lung 
adenocarcinoma classification that is based on multidisci-
plinary inputs followed the 2005 IASLC/American Society of 
Clinical Oncology BAC workshop. The concept was proposed 
to and received approval by the IASLC Board of Directors 
at the 2007 12th WCLC meeting, and subsequently received 
co-funding approval by the American Thoracic Society 
(ATS) and the European Respiratory Society (ERS). The 
first International Multidisciplinary Lung Adenocarcinoma 
Classification meeting took place at the Memorial Sloan 
Kettering Cancer Center (MSKCC, New York) during March 
28–31, 2008, to address the pathology, clinical, surgical, 
imaging, and molecular issues pertaining to lung adenocar-
cinoma classification. In addition to the pathologist members, 
more than 20 IASLC leaders in medical oncology, thoracic 
surgery, respirologists/pulmonologists, thoracic radiologists, 
and lung molecular biologists were invited and attended this 
meeting. After this meeting, a systematic literature review 
on all aspects of lung adenocarcinoma involving more than 
60 international lung cancer experts was completed during 
August 2008 to February 2009. This was followed by a second 
International Lung Adenocarcinoma Multidisciplinary meet-
ing in March 2009 at the MSKCC, during which the concept 
of “adenocarcinoma in situ (AIS) and “minimally invasive 
adenocarcinoma (MIA)” to replace the classical yet confusing 
term “BAC” was presented, extensively discussed and adopted 
by majority vote. In addition, the adenocarcinoma classifica-
tion was revised to group tumors based on the predominant 
histologic patterns while retaining the rare variants. After pre-
sentations of the new classification at the 13th WCLC (San 
Francisco, CA), ATS (San Diego, CA), and ERS (Vienna, 
Austria) meetings, the manuscript was finally published in the 
February 2011 issue of the Journal of Thoracic Oncology.25
After Dr. Masayuki Noguchi became the Chair of the 
panel, the committee devoted 2010 to the completion of the 
new classification manuscript, and conducted a study to assess 
the feasibility of adopting the “predominant pattern” approach 
FIGURE 4.  2004 World Health Organization Writing Committee, Lyon, March, 2004: left to right: back row: Keith Kerr, 
Henry Tazelaar, Robert Loire, Alan Burke, David Dail, Elisabeth Brambilla, Allen Gibbs, Francoise Galateau-Salle, Francoise 
Bijuit-Thivolet, Paul Kleihues, Mojgan Devouassoux-Shisheboran, Michael O. Kurrer, Peter Möller, Bryan Corrin, and Andrew 
Nicholson; middle row: Victor Roggli, Andrew Churg, Alex Marx, Fabio Menestrina, Masayuki Noguchi, Douglas Flieder, 
Adi Gazdar, Philip Haseltion, Konrad Muller-Hermelink, and Thomas Colby. Front row: Wilbur Franklin, Leslie Sobin, Yukio 
Shimosato, Nancy Harris, Tseng-tong Kuo, Philip Cagle, Fred Hirsch, and William Travis.
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for classifying lung adenocarcinoma with mixed histologic 
patterns. The results of this extensive study were the topic 
of discussion during the committee meetings in January and 
October of 2011 at Tsukuba, Japan. The study concluded that 
in pulmonary adenocarcinomas with classic morphology, 
which comprise the majority of cases, there was good repro-
ducibility in identifying a predominant pattern.26 However, 
more precise definitions and better education on interpretation 
of existing terminology are required to improve recognition of 
purely in situ disease, which becomes an area of increasing 
importance.
Dr. Ming-Sound Tsao became Chair of the Committee 
in October 2011 and focused the committee efforts and meet-
ings during 2011–2013 to two areas: (1) molecular classifica-
tion and biomarkers for treatment in NSCLC and (2) revision 
of classifications of other types of lung cancers aside from 
adenocarcinoma (Fig. 6). This period marked an impor-
tant extension of the Committee’s activities into the field of 
molecular pathology and biomarkers, especially on issues 
related to tissue utilization and assay standardization in bio-
marker testing. In collaboration with the College of American 
Pathologists and the Association of Molecular Pathologists, 
representative members of the IASLC Pathology Committee 
participated in the systematic review and publication of a 
guideline on molecular testing of epidermal growth factor 
receptor (EGFR) mutations and anaplastic lymphoma kinase 
(ALK) rearrangements in lung cancer patients.27 In addition, 
the Committee convened a workshop that resulted in the pub-
lication of the IASLC Atlas on ALK testing in lung cancer.28 
The Atlas was freely distributed to all registrants at the 15th 
WCLC and worldwide. The Atlas provided guidance on the 
use of fluorescence in situ hybridization for detecting ALK 
gene arrangement, as well as the use of alternative methods 
for ALK testing, selection of patients for testing, sample 
acquisition and processing, comparison of testing platforms, 
and reporting guidelines. Its goal was to help pathologists, 
laboratory scientists, and practicing physicians better under-
stand the background, protocol, and interpretation of results 
of ALK testing in patients with advanced NSCLC.
After the 15th WCLC meeting, Prof. Andrew Nicholson 
became the Chair of the Committee. As a priority in making 
further revision of the lung cancer histologic classification, 
the committee convened a multidisciplinary meeting at the 
MSKCC in New York on December 5–7, 2013. This meeting, 
led by Dr. William Travis, discussed proposals extensively 
for new classification system for lung cancer, in addition 
to the new classification of lung adenocarcinoma published 
in 2011. In addition to the Pathology Committee members, 
more than 20 IASLC leaders in clinical oncology and lung 
cancer genome scientists were invited to discuss critical 
issues that would impact on the new classification system 
being drafted for the 4th edition of the WHO Classification 
of Tumors of the Lung Pleura, Thymus and Heart to be pub-
lished in January 2015, with three members of the IASLC 
Pathology Committee, Drs. William Travis (lead editor), 
Elisabeth Brambilla, and Andrew Nicholson serving as the 
invited co-editors of this new book, and many committee 
members are lead co-authors of its major chapters.
HIGHLIGHTS OF PATHOLOGY RESEARCH 
DURING FOUR DECADES
1970–1979
One of the most important reports in pathology during 
1970s was by Oscar Aurbach et al.,29 who documented the 
significant decrease in the prevalence of bronchial epithelial 
FIGURE 5.  Pathology Panel meet-
ing for International Association for 
the Study of Lung Cancer/American 
Society of Clinical Oncology meet-
ing on Bronchioloalveolar Carcinoma, 
August 2004 at Armed Forces Institute 
of Pathology, Washington, DC. Left to 
right: back row: Wilbur Franklin, Erik 
Thunnissen, Philip Hasleton, Douglas 
Henderson, Ming-Sound-Tsao, Kim 
Geisinger, Douglas Flieder, William 
Travis, Bruce Johnson, Victor Roggli, 
and Robert Padera (Pathologist, 
Brigham & Women’s Hospital, Boston, 
MA); front row: Masayuki Noguchi, Y 
Minami (Thoracic Pathology Fellow, 
Tsukuba, Japan), Elisabeth Brambilla, 
and Ignacio Wistuba, Sanaa Hussein 
(Thoracic Pathology Fellow, Memorial 
Sloan Kettering Cancer Center).
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aberrations related to smoking during 1955–1960 and 1970–
1977, which coincides with the introduction of filter-tip 
cigarettes. Although the authors concluded that the finding 
supported a great drop during 25 years in the tar and nicotine 
content of the smoke from cigarettes consumed in the USA, 
it did not address the fact that such changes in cigarette man-
ufacture resulted in a shift in the histology and location of 
lung cancer from more common central squamous/small-cell 
carcinoma to peripheral adenocarcinoma. Another important 
development was reports that cytology examination of exfoli-
ated lung cancer cells can be accurately classified according 
to the histologic types diagnosed in resection specimens.30,31 
These reports led to the widespread adoption of cytology and 
the standard of care as the primary method of diagnosis espe-
cially in advanced lung cancer patients.
1980–1989
Two important areas of development occurred during 
the 1980s. The first was a proposal by the IASLC Pathology 
Committee to revise the 1981 WHO classification of small-
cell carcinoma by combining the “oat cell” and “intermediate” 
variants into a single “small cell” entity, and recognizing the 
“mixed small cell/large cell” and “combined small-cell carci-
noma” variants as new variants with potential prognostic and 
therapeutic implication.7,32 This new proposed classification 
has subsequently been adopted in the 1997 and 2004 WHO 
classifications. The other development was several institu-
tional and population-based studies that reported a changing 
incident pattern of histologic type of lung cancer during the 
1970s, with an increase in adenocarcinoma type.33,34
1990–1999
One of the important developments in lung cancer pathol-
ogy during this period was reports by Dr. Elisabeth Brambilla 
et al.35,36 on basaloid carcinoma as a new subtype of non–small-
cell carcinoma with distinct histopathologic features and very 
poor prognosis. Tumors that fit into this subtype were identified 
in 38 of 671 lung cancers that were resected over a 7-year period, 
with 22 stage 1 and 2 patients having a very poor median sur-
vival of 22 months. This tumor subtype has subsequently been 
incorporated into the WHO classification.1,8,21
In 1995, Drs. Noguchi and Shimosato published for 
the first time a pioneer paper45 on the pathologic prognostic 
indicator in small-cell (size: ≤2 cm) lung adenocarcinoma 
on a series of 236 surgically resected small 2 cm maximum 
diameter adenocarcinoma. They distinguished patients with 
type A (localized BAC) and type B (with foci of collapse) 
adenocarcinoma, in contrast with other subtypes with inva-
sion (C, D, E, and F), showed no lymph node metastasis 
and the most favorable prognosis with 100% 5-year sur-
vival. Based on this article, the concept of AIS and MIA 
emerged and these entities were subsequently proposed in 
the 2011 IASLC/ATS/ERS lung adenocarcinoma classifica-
tion.25 At the molecular pathology front, an important step 
was achieved toward the comprehension of multistep and 
multicentric carcinogenesis field cancerization with the dis-
covery of multiple clonal abnormalities in the bronchial epi-
thelium of patients with lung cancer.37 Multiple small clones 
or larger clonal patches containing clonally related molecu-
lar abnormalities are present in normal or slightly dysplas-
tic bronchial epithelium, distant to the tumor in smoking 
patient with lung cancer, indicating that normal epithelium 
of smokers is not normal.
2000–2009
In 2004, the new WHO classification “blue book” on 
Pathology and Genetics: Tumours of the Lung, Pleura, Thymus 
and Heart Classification was published.21 The new classifica-
tion recognized that 85% of adenocarcinoma are mixed type 
and do not fit within one defined histologic pattern, due to the 
frequent histologic heterogeneity. Importantly, EGFR muta-
tions that conferred sensitivity to EGFR tyrosine kinase inhib-
itor gefitinib was reported to be significantly more frequent 
in the BAC subtype.38 This publication has led to increased 
awareness among clinicians and pathologists on the impor-
tance of histologic typing of adenocarcinoma. The second 
highlight of this decade was the discovery of EML4-ALK gene 
fusion as a lung cancer driver oncogene,39 and subsequent 
clinical trials showing that ALK rearranged lung cancers are 
tractable by specific kinase inhibitors.40,41 This discovery con-
solidated the concept of “oncogene addiction” as a highly effi-
cacious strategy to treat cancer patients.
FIGURE 6.  2011–2013 International Association for the Study of Lung Cancer Pathology Committee discussing classifica-
tion for the 4th edition of World Health Organization classification during a meeting in Baltimore, MD. From left to right: 
Iver Peterson, Kim Geisinger, Yasushi Yatabe, Andre Moreira (invitee), Fred R. Hirsch, Alberto Marchevsky (invitee), Masayuki 
Noguchi, Andrew Nicholson, Lucian Chirieac, Ignacio Wistuba, Yuichi Ishikawa, Ming-Sound Tsao, William Travis, Elisabeth 
Brambilla, Mary Beth Beasley (invitee), Giuseppe Pelosi (invitee), David Hwang (invitee), Sylvie Lanteujoul (invitee), Kafai To, 
Mari Mino-Kenudson (invitee), Keith Kerr, Seena Aisner, Erik Thunissen, Victor Roggli, and Kenzo Hiroshima (invitee).
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2010–2013
In 2011, the IASLC, ATS, and ERS published a new 
proposal for classifying lung adenocarcinoma.25 This new 
classification, which was developed by the IASLC Pathology 
Committee and with extensive collaboration with a multi-
disciplinary team of clinicians and scientists from the three 
societies, proposed major changes to the 2004 WHO lung 
adenocarcinoma classification that would bring greater clini-
cal relevance for the classification and practical application in 
the age of molecular pathology and targeted therapy. Major 
changes included the proposal to discontinue the use of the 
term BAC from the classification system and replace it with 
new categories of AIS and MIA, to reflect lesions that may 
have 100% survival if completely resected by surgery. The new 
proposal also for the first time provides recommendations on 
how to approach classification in small biopsy/cytology speci-
mens, and guidelines for good practice in pathologic work-up 
and diagnosis of lung cancer specimens. Subsequent to the 
publication of this new proposal, several independent studies 
have validated the prognostic relevance of the classification.
CONCLUSION
The multidisciplinary approach that represents the 
IASLC culture in research, education, and practice in clinical 
management of lung cancer patients has paved the way for 
integrating pathology practice into the new era of personal-
ized cancer care based on more accurate diagnosis, molecular 
characterization of tumor, and effective targeted therapy. As 
the molecular genotype and phenotype of different histologic 
types of lung cancers are being deciphered, there is expecta-
tion that the IASLC Pathology Committee will continue to 
lead in improving lung cancer diagnosis for better survival 
outcome of lung cancer patients.
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